search
Back to results

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Primary Purpose

Primary Immune Thrombocytopenia (ITP)

Status
Recruiting
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
TPO-RAs
TPO-RAs combining anti-CD 20 monoclonal antibody
Sponsored by
Institute of Hematology & Blood Diseases Hospital, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Immune Thrombocytopenia (ITP) focused on measuring immune thrombocytopenia, autoantibody, eltrombopag, rituximab

Eligibility Criteria

6 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 6-17 years old (including both ends), male and female; Patients aged 6-11 years (including values at both ends) were diagnosed with chronic ITP, and patients aged 12-17 years (including values at both ends) were diagnosed with persistent or chronic ITP, with platelet counts less than 20×109/L; Patients did not respond to glucocorticoid therapy or relapsed. Previous ITP treatment may include, but is not limited to, glucocorticoids, immunomodulators (IVIG), azathioprine, danazole, cyclophosphamide and immunomodulators. Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, TPO agonist (TPO-RA), azathioprine, danazole, cyclosporin A, mycophenate) must be completed or dose stabilized before enrollment, and therapeutic dose should not be increased after enrollment (e.g. The glucocorticoid dose should be stable for ≥14 days and the immunosuppressant dose should be stable for > 3 months before the first administration of the study drug. TPO drugs should be stopped > 1 month, TPO-RA drugs should be stopped > 1 month). No infectious fever (including but not limited to lung infection) in the past 1 month. Laboratory examination of coagulation function should show that the prothrombin time (PT) and activated partial thrombin time (aPTT) values did not exceed 20% of the normal laboratory value range; No history of abnormal coagulation except for ITP. WBC count, neutrophil absolute value and hemoglobin should be within the normal range of laboratory values. No other abnormality except for ITP. Other exceptions except the following: If the anemia is clearly caused by excessive blood loss associated with ITP. If the increase in WBC count/neutrophil absolute value was clearly due to steroid therapy. Understand the study procedure and voluntarily sign the informed consent. For subjects aged 6-7 (including both ends), parents/guardians understand the study procedure and voluntarily sign the informed consent in person, and subjects are encouraged to participate in the informed process and voluntarily sign the informed consent in person; For subjects aged 8-16 (including both ends), parents/guardians and subjects themselves should understand the study procedure and voluntarily sign the informed consent in person; For the minor subjects > 16 years old, if the subjects rely on their own income as the main source of living, they are regarded as persons with full capacity for civil conduct and can independently carry out legal acts. The subjects can sign informed consent on the premise that they understand the research procedures and are willing to do so; For minor subjects > 16 years old, if the subjects do not rely on their own income as the main source of living, they cannot be regarded as persons with full capacity for civil conduct and cannot independently carry out legal acts. Parents/guardians and subjects should understand the study procedures and voluntarily sign the informed consent in person. Exclusion Criteria: Subjects who has any history of arterial/venous thrombosis and the following risk factors including clotting factor V Leiden disease, ATIII deficiency, antiphospholipid syndrome, etc.. Subjects known to have failed all standard TPO-RAs treatments. Subjects known to have taken anti-CD20 antibodytreatment within 3 months prior to initial use of the study drug. Within 2 weeks prior to the initial use of the study drug, subjects were treated with medications (including but not limited to aspirin, aspirin containing compounds, clopidogrel, salicylate, and/or NSAIDs) or anticoagulants that had an impact on platelet function for > 3 consecutive days. Subjects known to have participated in other investigational clinical trials within 3 months prior to first use of investigational drug. Suffering from severe, progressive, uncontrolled kidney, liver, gastrointestinal, endocrine, lung, heart, nervous system, brain or psychiatric disorders. HIV infection with laboratory or clinical diagnosis. Previous history of hepatitis C, chronic hepatitis B infection, or evidence of active hepatitis. Laboratory tests at the screening stage indicate seropositivity for hepatitis C or hepatitis B seropositivity (HBsAg positive). In addition, if HBsAg is negative but HBcAb is positive (regardless of HBsAb status), HBV DNA testing is required, and if positive, the subject should be excluded. During the screening period, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase were more than 1.5 times of the upper limit of normal value, serum creatinine and bilirubin were more than 1.2 times of the upper limit of normal value, and serum albumin was less than 10% of the lower limit of normal value. Bone marrow biopsy results within 6 months before enrollment showed that myelofibrosis score MF≥2. There is a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements. Any medical history or condition that the investigator deems unsuitable for participation in the study.

Sites / Locations

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

efficacy of TPO-RAs

efficacy of TPO-RAs combining anti-CD 20 monoclonal antibody

Arm Description

After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag administration was an oral 37.5 mg (6-11 years old) or 50 mg (12-17 years old) once daily. The initial dose of hetrombopag administration was an oral 3.75 mg (6-11 years old) or 5mg (12-17 years old) once daily in all participants. The initial dose of avatrombopag administration was an oral 10 mg (<30kg) or 20mg (≥30kg) once daily in all participants. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the TPO-RAs will stop until the platelet count <100×10^9/L. Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24.

After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as patients in TPO-RAs monotherapy group. The dose of TPO-RAs was adjusted according to the subject platelet count. Two kinds of anti-CD 20 monoclonal antibody could be used in this study. All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment. Subjects weighing less than 30kg will be given rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Ps. Participants in the eltrombopag monotherapy group who have platelet count < 20×10^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of rituximab 375mg/m2. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24.

Outcomes

Primary Outcome Measures

Treatment response
Number of participants achieving a platelet count >=30×10^9/L and at least doubling of the baseline count at Week 4, Week 8, and Week 12.

Secondary Outcome Measures

Long-term treatment response
The proportion of subjects who achieve efficacy (R) at 24weeks of treatment.
Withdrawal of eltrombopag
The proportion of subjects who successfully stop TPO-RAs within 24 weeks.
Drug efficacy 1
Number of participants achieving a platelet count >=30×10^9/L at week 4, week 8, week 12 and week 24 in ITP patients with or without positive autoantibody.
Time to Response
The time required from the start of treatment to the first time a subject's platelet count was greater than or equal to 30×109/L and at least a two-fold increase from the baseline platelet count.
Duration of response
Total duration of subject's platelet count ≥30×109/L
Drug efficacy 2
Number of participants achieving a platelet count >=50×10^9/L at week 4, week 8, week 12 and week 24
emergency treatment
The proportion of subjects receiving emergency treatment
Evaluation of effectiveness
Number of participants that reduced or discontinued baseline concomitant ITP medications during the whole 24 weeks.
Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale.
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.
Number of participants with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP.
The bleeding scale for pediatric patients with ITP is a measure of bleeding severity with the following grades: Grade 1 (minor) Minor bleeding, few petechiae (≤100 total) and/or ≤5 small bruises (≤3 cm in diameter), no mucosal bleeding;Grade 2 (mild) Mild bleeding, many petechiae (>100 total) and/or >5 large bruises (>3 cm in diameter), no mucosal bleeding;Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle;Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb>2 g/dL or suspected internal hemorrhage;
Health-related quality of life survey of subjects(HRQoL)-1
In all participants ,use ITP-PAQ (ITP Patient Assessment Questionnaire) to assess the HRQoL before and after treatment.
Health-related quality of life survey of subjects(HRQoL)-2
In all participants ,use FACIT-F(functional assessment of chronic illness therapy- fatigue)to assess the HRQoL before and after treatment.
Health-related quality of life survey of subjects(HRQoL)-3
In all participants ,use Kids' ITP tool KIT、to assess the HRQoL before and after treatment.
Health-related quality of life survey of subjects(HRQoL)-4
In all participants ,use Pediatric Quality of Life Inventory PedsQL to assess the HRQoL before and after treatment.

Full Information

First Posted
November 13, 2022
Last Updated
October 17, 2023
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Beijing Children's Hospital, Tianjin People's Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University
search

1. Study Identification

Unique Protocol Identification Number
NCT05718856
Brief Title
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
Official Title
A Multicenter, Randomized, Open-label StudyTo Compare The Efficacy And Safety Of TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in Persistent or Chronic Pediatric ITP Patients Who Failed or Relapse After Hormone Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 23, 2023 (Actual)
Primary Completion Date
May 14, 2024 (Anticipated)
Study Completion Date
November 14, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Beijing Children's Hospital, Tianjin People's Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
This multicenter randomized, open-label study aime to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or chronic pediatric ITP patients who had not responded to or had relapsed after previous hormone treatment.
Detailed Description
The primary objective of this study was to evaluate the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody treating previously treated pediatric ITP patients compared to TPO-RAs. The secondary objective was to evaluate the efficacy of TPO-RAs combining anti-CD 20 monoclonal antibody in pediatric ITP patients with positive autoantibody compared to TPO-RAs.In addition, health-related quality of life (HRQoL) measure was assessed in all participants. 166 eligible subjects were randomized to either TPO-RAs combining anti-CD 20 monoclonal antibody or TPO-RAs treatment in 1:1 ratio. 83 enrolled patients are randomly picked up to take TPO-RAs combining with anti-CD 20 monoclonal antibody at the indicated dose. 83 enrolled patients are randomly picked up to take TPO-RAs at the indicated dose. Three TPO-RAs could be used in this study, including eltrombopag, hetrombopag and avatrombopag. The initial dose of eltrombopag administration was an oral 37.5 mg (6-11 years old) or 50 mg (12-17 years old) once daily in all participants. The initial dose of hetrombopag administration was an oral 3.75 mg (6-11 years old) or 5mg (12-17 years old) once daily in all participants. The initial dose of avatrombopag administration was an oral 10 mg (<30kg) or 20mg (≥30kg) once daily in all participants.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. Two kinds of anti-CD 20 monoclonal antibody could be used in this study, including Rituximab and Ortuzumab.Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Ps.Participants in the TPO-RAs monotherapy group who have platelet count < 20×10^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2.Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Immune Thrombocytopenia (ITP)
Keywords
immune thrombocytopenia, autoantibody, eltrombopag, rituximab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
166 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
efficacy of TPO-RAs
Arm Type
Active Comparator
Arm Description
After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag administration was an oral 37.5 mg (6-11 years old) or 50 mg (12-17 years old) once daily. The initial dose of hetrombopag administration was an oral 3.75 mg (6-11 years old) or 5mg (12-17 years old) once daily in all participants. The initial dose of avatrombopag administration was an oral 10 mg (<30kg) or 20mg (≥30kg) once daily in all participants. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the TPO-RAs will stop until the platelet count <100×10^9/L. Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24.
Arm Title
efficacy of TPO-RAs combining anti-CD 20 monoclonal antibody
Arm Type
Experimental
Arm Description
After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as patients in TPO-RAs monotherapy group. The dose of TPO-RAs was adjusted according to the subject platelet count. Two kinds of anti-CD 20 monoclonal antibody could be used in this study. All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment. Subjects weighing less than 30kg will be given rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Ps. Participants in the eltrombopag monotherapy group who have platelet count < 20×10^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of rituximab 375mg/m2. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24.
Intervention Type
Drug
Intervention Name(s)
TPO-RAs
Other Intervention Name(s)
TPO-R agonists
Intervention Description
After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the TPO-RAs will stop until the platelet count <100×10^9/L.
Intervention Type
Drug
Intervention Name(s)
TPO-RAs combining anti-CD 20 monoclonal antibody
Other Intervention Name(s)
TPO-R agonist & anti-CD 20 monoclonal antibody
Intervention Description
After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Ps.Participants in the TPO-RAs monotherapy group who have platelet count < 20×10^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater.
Primary Outcome Measure Information:
Title
Treatment response
Description
Number of participants achieving a platelet count >=30×10^9/L and at least doubling of the baseline count at Week 4, Week 8, and Week 12.
Time Frame
From the start of study treatment (Day 1) up to the end of week 4, week 8 and week 12.
Secondary Outcome Measure Information:
Title
Long-term treatment response
Description
The proportion of subjects who achieve efficacy (R) at 24weeks of treatment.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Withdrawal of eltrombopag
Description
The proportion of subjects who successfully stop TPO-RAs within 24 weeks.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Drug efficacy 1
Description
Number of participants achieving a platelet count >=30×10^9/L at week 4, week 8, week 12 and week 24 in ITP patients with or without positive autoantibody.
Time Frame
From the start of study treatment (Day 1) up to the end of week 4, week 8, week 12 and week 24.
Title
Time to Response
Description
The time required from the start of treatment to the first time a subject's platelet count was greater than or equal to 30×109/L and at least a two-fold increase from the baseline platelet count.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Duration of response
Description
Total duration of subject's platelet count ≥30×109/L
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Drug efficacy 2
Description
Number of participants achieving a platelet count >=50×10^9/L at week 4, week 8, week 12 and week 24
Time Frame
From the start of study treatment (Day 1) up to the end of week 4, week 8, week 12 and week 24.
Title
emergency treatment
Description
The proportion of subjects receiving emergency treatment
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Evaluation of effectiveness
Description
Number of participants that reduced or discontinued baseline concomitant ITP medications during the whole 24 weeks.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale.
Description
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Number of participants with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP.
Description
The bleeding scale for pediatric patients with ITP is a measure of bleeding severity with the following grades: Grade 1 (minor) Minor bleeding, few petechiae (≤100 total) and/or ≤5 small bruises (≤3 cm in diameter), no mucosal bleeding;Grade 2 (mild) Mild bleeding, many petechiae (>100 total) and/or >5 large bruises (>3 cm in diameter), no mucosal bleeding;Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle;Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb>2 g/dL or suspected internal hemorrhage;
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Health-related quality of life survey of subjects(HRQoL)-1
Description
In all participants ,use ITP-PAQ (ITP Patient Assessment Questionnaire) to assess the HRQoL before and after treatment.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Health-related quality of life survey of subjects(HRQoL)-2
Description
In all participants ,use FACIT-F(functional assessment of chronic illness therapy- fatigue)to assess the HRQoL before and after treatment.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Health-related quality of life survey of subjects(HRQoL)-3
Description
In all participants ,use Kids' ITP tool KIT、to assess the HRQoL before and after treatment.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.
Title
Health-related quality of life survey of subjects(HRQoL)-4
Description
In all participants ,use Pediatric Quality of Life Inventory PedsQL to assess the HRQoL before and after treatment.
Time Frame
From the start of study treatment (Day 1) up to the end of week 24.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 6-17 years old (including both ends), male and female; Patients aged 6-11 years (including values at both ends) were diagnosed with chronic ITP, and patients aged 12-17 years (including values at both ends) were diagnosed with persistent or chronic ITP, with platelet counts less than 20×109/L; Patients did not respond to glucocorticoid therapy or relapsed. Previous ITP treatment may include, but is not limited to, glucocorticoids, immunomodulators (IVIG), azathioprine, danazole, cyclophosphamide and immunomodulators. Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, TPO agonist (TPO-RA), azathioprine, danazole, cyclosporin A, mycophenate) must be completed or dose stabilized before enrollment, and therapeutic dose should not be increased after enrollment (e.g. The glucocorticoid dose should be stable for ≥14 days and the immunosuppressant dose should be stable for > 3 months before the first administration of the study drug. TPO drugs should be stopped > 1 month, TPO-RA drugs should be stopped > 1 month). No infectious fever (including but not limited to lung infection) in the past 1 month. Laboratory examination of coagulation function should show that the prothrombin time (PT) and activated partial thrombin time (aPTT) values did not exceed 20% of the normal laboratory value range; No history of abnormal coagulation except for ITP. WBC count, neutrophil absolute value and hemoglobin should be within the normal range of laboratory values. No other abnormality except for ITP. Other exceptions except the following: If the anemia is clearly caused by excessive blood loss associated with ITP. If the increase in WBC count/neutrophil absolute value was clearly due to steroid therapy. Understand the study procedure and voluntarily sign the informed consent. For subjects aged 6-7 (including both ends), parents/guardians understand the study procedure and voluntarily sign the informed consent in person, and subjects are encouraged to participate in the informed process and voluntarily sign the informed consent in person; For subjects aged 8-16 (including both ends), parents/guardians and subjects themselves should understand the study procedure and voluntarily sign the informed consent in person; For the minor subjects > 16 years old, if the subjects rely on their own income as the main source of living, they are regarded as persons with full capacity for civil conduct and can independently carry out legal acts. The subjects can sign informed consent on the premise that they understand the research procedures and are willing to do so; For minor subjects > 16 years old, if the subjects do not rely on their own income as the main source of living, they cannot be regarded as persons with full capacity for civil conduct and cannot independently carry out legal acts. Parents/guardians and subjects should understand the study procedures and voluntarily sign the informed consent in person. Exclusion Criteria: Subjects who has any history of arterial/venous thrombosis and the following risk factors including clotting factor V Leiden disease, ATIII deficiency, antiphospholipid syndrome, etc.. Subjects known to have failed all standard TPO-RAs treatments. Subjects known to have taken anti-CD20 antibodytreatment within 3 months prior to initial use of the study drug. Within 2 weeks prior to the initial use of the study drug, subjects were treated with medications (including but not limited to aspirin, aspirin containing compounds, clopidogrel, salicylate, and/or NSAIDs) or anticoagulants that had an impact on platelet function for > 3 consecutive days. Subjects known to have participated in other investigational clinical trials within 3 months prior to first use of investigational drug. Suffering from severe, progressive, uncontrolled kidney, liver, gastrointestinal, endocrine, lung, heart, nervous system, brain or psychiatric disorders. HIV infection with laboratory or clinical diagnosis. Previous history of hepatitis C, chronic hepatitis B infection, or evidence of active hepatitis. Laboratory tests at the screening stage indicate seropositivity for hepatitis C or hepatitis B seropositivity (HBsAg positive). In addition, if HBsAg is negative but HBcAb is positive (regardless of HBsAb status), HBV DNA testing is required, and if positive, the subject should be excluded. During the screening period, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase were more than 1.5 times of the upper limit of normal value, serum creatinine and bilirubin were more than 1.2 times of the upper limit of normal value, and serum albumin was less than 10% of the lower limit of normal value. Bone marrow biopsy results within 6 months before enrollment showed that myelofibrosis score MF≥2. There is a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements. Any medical history or condition that the investigator deems unsuitable for participation in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lei Zhang
Phone
+86 13502118379
Email
zhanglei1@ihcams.ac.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lei Zhang, M.D.,Ph.D
Organizational Affiliation
Institute of Hematology & Blood Diseases Hospital, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
City
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ting Sun
Phone
+8615822339131
Email
sunting@ihcams.ac.cn
First Name & Middle Initial & Last Name & Degree
Lei Zhang

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31794604
Citation
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, Kuhne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966. Erratum In: Blood Adv. 2020 Jan 28;4(2):252.
Results Reference
result
PubMed Identifier
19005182
Citation
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
Results Reference
result
PubMed Identifier
34587675
Citation
Working Group of Chinese Guideline for the Diagnosis and Treatment of Childhood Primary Immune Thrombocytopenia; Subspecialty Group of Hematologic Diseases, the Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics. [Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021)]. Zhonghua Er Ke Za Zhi. 2021 Oct 2;59(10):810-819. doi: 10.3760/cma.j.cn112140-20210509-00397. Chinese.
Results Reference
result
PubMed Identifier
20739054
Citation
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23. Erratum In: Lancet. 2011 Jan 29;377(9763):382.
Results Reference
result
PubMed Identifier
29042367
Citation
Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Erratum In: Blood. 2018 Feb 8;131(6):709.
Results Reference
result
PubMed Identifier
27734464
Citation
Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, Zhang X, Hou M. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017 Jan;176(1):101-110. doi: 10.1111/bjh.14380. Epub 2016 Oct 13.
Results Reference
result
PubMed Identifier
34605871
Citation
Cheng X, Fu L, Ma J, Gu H, Chen Z, Zhao L, Wang X, Wu R. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Adv. 2021 Oct 12;5(19):3799-3806. doi: 10.1182/bloodadvances.2020004110.
Results Reference
result
PubMed Identifier
33115308
Citation
Qu M, Zhou J, Yang SJ, Zhou ZP. Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis. J Int Med Res. 2020 Oct;48(10):300060520962348. doi: 10.1177/0300060520962348.
Results Reference
result
PubMed Identifier
34962697
Citation
Ayad N, Grace RF, Al-Samkari H. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. Pediatr Blood Cancer. 2022 Mar;69(3):e29447. doi: 10.1002/pbc.29447. Epub 2021 Dec 28.
Results Reference
result
PubMed Identifier
22338149
Citation
Sui T, Zhang L, Zhou ZP, Xue F, Ge J, Yang RC. [Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia]. Zhonghua Xue Ye Xue Za Zhi. 2011 Sep;32(9):583-6. Chinese.
Results Reference
result
PubMed Identifier
25543701
Citation
Liu X, Huang Y, Chen Y, Liu W, Xue F, Zhang L, Yang R. [Clinical analysis of lower doses rituximab for children primary immune thrombocytopenia]. Zhonghua Xue Ye Xue Za Zhi. 2014 Dec;35(12):1079-82. doi: 10.3760/cma.j.issn.0253-2727.2014.12.007. Chinese.
Results Reference
result
PubMed Identifier
31770441
Citation
Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, Gonzalez-Lopez TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.
Results Reference
result
PubMed Identifier
26688484
Citation
Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015 Aug;2(8):e315-25. doi: 10.1016/S2352-3026(15)00114-3. Epub 2015 Jul 28. Erratum In: Lancet Haematol. 2015 Oct;2(10):e407.
Results Reference
result
PubMed Identifier
26231455
Citation
Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28. Erratum In: Lancet. 2015 Oct 24;386(10004):1630.
Results Reference
result

Learn more about this trial

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

We'll reach out to this number within 24 hrs